Recurrent Wheezing in Infants: Risk Factors and Prevention With Probiotics.
Respiratory Tract Diseases, Wheezing
About this trial
This is an interventional treatment trial for Respiratory Tract Diseases focused on measuring wheezing, immune system, cytokines, probiotics, infants.
Eligibility Criteria
Inclusion Criteria:
- Infants aged six months to two years incomplete.
- Infants who have recurrent wheezing in the past 3 months.
- Infants under use of proper technique of inhaled corticosteroids: beclomethasone HFA spray - 50 mg - 2 times daily (100 mg / day) with spacer and face mask.
Exclusion Criteria:
- Patients who present congenital airway malformations, cystic fibrosis, chronic diseases in other systems, perinatal respiratory problems, allergy to the protein in cow's milk, intrathoracic tumors, Tuberculosis and Pulmonary Congenital immunodeficiencies, children who were premature: <37 weeks gestational age.
- Use of other products containing probiotics in its composition with previous exposure or even study period.
- Infant in use of anti-leukotrienes.
- Use recent antibiotic.
Sites / Locations
- Federal University of Pernambuco
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Probiotics & Beclomethasone
Beclomethasone & Placebo
It will be supplied in lyophilized form, in each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days. Beclomethasone HFA 50mcg spray - 100 mcg/day as initial treatment for primary and wheezing in this age group, at doses considered minimal, for 4 months.
The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics. It will be supplied in lyophilized form in each sachet containing 1 g of placebo, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.